|
| 产品描述 |
| Orantinib, also known as TSU-68；SU6668, is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Check for active clinical trials or closed clinical trials using this agent. |
| 化学结构 |
 |
| 化学名称 |
| (Z)-3-(2,4-dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid |
| SMILES Code |
| O=C(O)CCC1=C(C)NC(/C=C2C(NC3=C2C=CC=C3)=O)=C1C |
| 基本信息 |
产品编号:XM334
产品名称:Orantinib
别名:TSU68; TSU 68; TSU-68; SU6668; SU 6668; SU-6668; NSC 702827; Orantinib.
CAS#:252916-29-3
分子式:C28H26N4O4
精确分子量:482.19541
分子量:482.53
|
| 物化性质 |
外观: 白色或类白色固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
